OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Marine fungus-derived aniquinazolin B could be a potential opioid alternative

Opioids have long been known as natural substances with substantial pharmacological effect. They have been used as effective painkillers.

July 17, 2024

Born out of Omega push for pandemic treatments, Aerium Therapeutics enters long Covid R&D

Aerium Therapeutics, which Omega Funds seeded in 2021 and unveiled in spring 2022 to take on Covid-19 with new monoclonal antibodies, will attempt to treat

August 5, 2023

Novel SARS-CoV-2 mutations found in floodwaters near homeless communities

Study highlights the detection of SARS-CoV-2 RNA and novel spike gene mutations in flood control channels affected by homeless populations, demonstrating the value of environmental

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.